Clinical Trials- Carcinoid

 TITLE  PHASE  CONTACT  LOCATION
A Phase 3, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Double- Blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in  Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy(Lexicon LX1606.1-301-CS)  III  Gladys Pierce RN
gladys.pierce@nmhs.org
402-354-5129
 Nebraska Methodist Hospital,
Omaha NE
       

 

 

 

 

 

 

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software